AstraZeneca and Lilly Establish Development and Commercialization Partnership for Alzheimer’s Treatment

AstraZeneca and Lilly Establish Development and Commercialization Partnership for Alzheimer’s Treatment
Alzheimer's TreatmentAstraZeneca and Eli Lilly and Company have reached an agreement for the development and commercialization of the oral beta secretes cleaving enzyme (BACE) inhibitor, AZD3293, which might become a viable treatment for Alzheimer's disease. The oral therapy is expected to prevent the formation of amyloid plaque, which is comprised of peptides called amyloid beta, and slow the disease progression.

The agreement established stipulates that AstraZeneca will pay up to $500 million in development and regulatory milestone payments. Lilly announced that it is planning on receiving the first milestone payment of $50 million in the first half of 2015. Future costs will be equally shared by both companies, including net global revenues post-launch.

“Alzheimer’s disease is one of the biggest challenges facing medical science today and BACE inhibitors have the potential to target one of the key drivers of disease progression," said the executive vice president of Innovative Medicines & Early Development at AstraZeneca, Mene Pangalos. "We are looking forward to working with Lilly, an organization with a long term commitment to and e

Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *